Biogen Inc. (ETR:IDP)
108.60
-0.15 (-0.14%)
Jun 25, 2025, 5:35 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
Multiple Sclerosis | 4.23B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Multiple Sclerosis Growth | -8.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other | 2.59B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Growth | 4.88% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Disease | 2.13B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Rare Disease Growth | 19.28% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biosimilars | 777.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Biosimilars Growth | 0.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Alzheimer's Disease | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
United States | 3.25B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
United States Growth | 1.85% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International | 3.98B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
International Growth | -0.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|